Niethard, M.; Knebel, C.; Leithner, A.; Tunn, P.-U.; Schoon, J.; Reichardt, P.; Pogkas, A.; Szkandera, J.; Pink, D.; Andreou, D.
What Is the Impact of Multimodal Treatment in Patients with Leiomyosarcoma of Bone? A Multicenter Study of 35 Patients with an Ultra-Rare Tumor Entity. Cancers 2024, 16, 1633.
https://doi.org/10.3390/cancers16091633
AMA Style
Niethard M, Knebel C, Leithner A, Tunn P-U, Schoon J, Reichardt P, Pogkas A, Szkandera J, Pink D, Andreou D.
What Is the Impact of Multimodal Treatment in Patients with Leiomyosarcoma of Bone? A Multicenter Study of 35 Patients with an Ultra-Rare Tumor Entity. Cancers. 2024; 16(9):1633.
https://doi.org/10.3390/cancers16091633
Chicago/Turabian Style
Niethard, Maya, Carolin Knebel, Andreas Leithner, Per-Ulf Tunn, Janosch Schoon, Peter Reichardt, Athanasios Pogkas, Joanna Szkandera, Daniel Pink, and Dimosthenis Andreou.
2024. "What Is the Impact of Multimodal Treatment in Patients with Leiomyosarcoma of Bone? A Multicenter Study of 35 Patients with an Ultra-Rare Tumor Entity" Cancers 16, no. 9: 1633.
https://doi.org/10.3390/cancers16091633
APA Style
Niethard, M., Knebel, C., Leithner, A., Tunn, P. -U., Schoon, J., Reichardt, P., Pogkas, A., Szkandera, J., Pink, D., & Andreou, D.
(2024). What Is the Impact of Multimodal Treatment in Patients with Leiomyosarcoma of Bone? A Multicenter Study of 35 Patients with an Ultra-Rare Tumor Entity. Cancers, 16(9), 1633.
https://doi.org/10.3390/cancers16091633
